| Q39405736 | 2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil |
| Q36891530 | Advancing outcome measures for the new era of drug development in cystic fibrosis |
| Q36135251 | Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy |
| Q35681874 | Application of biomarkers to clinical trials in systemic sclerosis |
| Q36284659 | Biomarkers and surrogate endpoints in kidney disease |
| Q36045270 | Biomarkers and surrogate markers: an FDA perspective |
| Q36439163 | Blood pressure as an example of a biomarker that functions as a surrogate |
| Q38623810 | Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. |
| Q64256361 | Conditional approval of cancer drugs in Canada: accountability and impact on public funding |
| Q38791641 | Current Status of Celiac Disease Drug Development |
| Q52911638 | Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization. |
| Q24796010 | Losartan and diabetic nephropathy: commentaries on the RENAAL study |
| Q34475498 | OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. |
| Q37730520 | Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs |
| Q39534931 | Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases |
| Q37964935 | Role of randomized phase III trials in an era of effective targeted therapies |
| Q57065992 | Sobrediagnóstico y sobretratamiento en el ámbito cardiovascular: factores de riesgo, no enfermedades |
| Q57173000 | Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials |
| Q35792872 | Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy |
| Q35058214 | The challenges of conducting clinical endpoint studies |
| Q36087521 | Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study |
| Q36891520 | Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis |